The Second Affiliated Hospital Zhejiang University School of Medicine
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（PROFOUND） | cancer, neoplasm | Recruiting | Not stated | 2026-09-11 | NCT06217900 | |
| Sphere-9 PAF China Study | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Not yet recruiting | Not applicable | 2026-08-27 | NCT07789925 | |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-07-27 | NCT06095583 | |
| 24-Week Recurrence Rate of Gout Following Firsekibart Treatment | Gout Flare | Not yet recruiting | Not applicable | 2026-06-04 | NCT07625514 | |
| Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, persistent atrial fibrillation | Recruiting | Phase 4 | 2026-04-02 | NCT07508618 | |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-01 | NCT07059650 | |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, head and neck cancer, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT04930432 | |
| Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-23 | NCT04208347 | |
| A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-01-15 | NCT04649489 | |
| SAVE-PCI: NyokAssist™ Small-Bore VAD vs. IABP in Elective High-Risk PCI | High-Risk PCI | Active, not recruiting | Not applicable | 2026-01-12 | NCT07010965 | |
| A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2025-12-15 | NCT07182682 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 | 2025-01-08 | NCT06556394 | |
| Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-12-30 | NCT05712902 | |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 3 | 2024-12-27 | NCT06363994 | |
| CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection | hepatocellular carcinoma | Recruiting | Phase 1 | 2024-08-19 | NCT06560827 | |
| VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up （VITAL） | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Not yet recruiting | Not stated | 2023-08-04 | NCT05977257 | |
| Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC | MRD | Recruiting | Phase 2 | 2022-09-14 | NCT05536505 | |
| Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2022-08-31 | NCT05334277 |